TMC-310911 | ASC-09 | CAS#1000287-05-7 | HIV protease inhibitor

MedKoo Cat#: 529115 | Name: TMC-310911

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TMC-310911, also known as ASC-09, is an HIV protease inhibitor potentially for the treatment of HIV infection.

Chemical Structure

TMC-310911

CAS#1000287-05-7

Theoretical Analysis

MedKoo Cat#: 529115

Name: TMC-310911

CAS#: 1000287-05-7

Chemical Formula: C38H53N5O7S2

Exact Mass: 755.3386

Molecular Weight: 755.99

Elemental Analysis: C, 60.37; H, 7.07; N, 9.26; O, 14.81; S, 8.48

Price and Availability

Size	Price	Availability
1mg	USD 90.00	Ready to ship
5mg	USD 250.00	Ready to ship
10mg	USD 450.00	Ready to ship
25mg	USD 950.00	Ready to ship
50mg	USD 1,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TMC-310911; ASC-09; TMC310911; ASC09; TMC 310911; ASC 09

IUPAC/Chemical Name

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((2-((1-cyclopentylpiperidin-4-yl)amino)-N-isobutylbenzo[d]thiazole)-6-sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate

InChi Key

JQUNFHFWXCXPRK-AMMMHQJVSA-N

InChi Code

InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1

SMILES Code

O=C(O[C@H]1CO[C@@]2([H])OCC[C@]21[H])N[C@@H](CC3=CC=CC=C3)[C@H](O)CN(S(=O)(C4=CC=C5N=C(NC6CCN(C7CCCC7)CC6)SC5=C4)=O)CC(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YXM211205

QC Data

View QC data: current batch, Lot#YXM211205

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

TMC310911 is a potent HIV type-1 (HIV-1) protease inhibitor with EC50 values ranging from 2.2 nM to 14.2 nM for wild-type HIV-1.

In vitro activity:

The in vitro activity of TMC310911 against laboratory HIV strains was evaluated using acutely infected MT4 cells, PBMCs, and M/M cells. The TMC310911 EC50 values against WT HIV-1 ranged from 2.2 to 14 nM, and the corresponding EC90 values ranged from 5.0 to 94.7 nM. The TMC310911 CC50 for MT4 cells was 9.9 μM (interquartile ranges [IQR] = 8.57 to 12.19), with a resulting SI of 692. The TMC310911 EC50 values increased by a median factor of 7 in the presence of 50% human serum. In further analyses of the antiviral activity of TMC310911, an EC50 FC > 4 and an EC50 FC > 10 were used as criteria to describe potential resistance to TMC310911. The TMC310911 EC50 FC was ≤4 for most (82%; n = 1,658) of the 2,011 isolates with decreased susceptibility (FC > 10) to at least one of the current PIs and was between 4 and 10 for 14% (n = 277) of isolates. The activity against a comprehensive panel of PI-resistant mutants and the limited in vitro selection of resistant viruses under drug pressure suggest that TMC310911 represents a potential drug candidate for the management of HIV-1 infection for a broad range of patients, including those with multiple PI resistance. Reference: Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. https://pubmed.ncbi.nlm.nih.gov/21896904/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 755.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. PMID: 21896904; PMCID: PMC3232804.

In vitro protocol:

In vivo protocol:

TBD

1: Soremekun OS, Omolabi KF, Adewumi AT, Soliman ME. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective. Future Sci OA. 2020 Nov 9;7(1):FSO640. doi: 10.2144/fsoa-2020-0079. PMID: 33432269; PMCID: PMC7651988. 2: Ibrahim MAA, Abdelrahman AHM, Allemailem KS, Almatroudi A, Moustafa MF, Hegazy MF. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Protein J. 2021 Jun;40(3):296-309. doi: 10.1007/s10930-020-09945-6. Epub 2021 Jan 2. PMID: 33387249; PMCID: PMC7776322. 3: Keretsu S, Bhujbal SP, Cho SJ. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Sci Rep. 2020 Oct 19;10(1):17716. doi: 10.1038/s41598-020-74468-0. PMID: 33077821; PMCID: PMC7572583. 4: Mahdian S, Ebrahim-Habibi A, Zarrabi M. Drug repurposing using computational methods to identify therapeutic options for COVID-19. J Diabetes Metab Disord. 2020 May 30;19(2):691-699. doi: 10.1007/s40200-020-00546-9. Erratum in: J Diabetes Metab Disord. 2023 Jul 10;22(2):1815. doi: 10.1007/s40200-023-01248-8. PMID: 32837954; PMCID: PMC7261216.